SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) today announced that the Company will conduct a multi-center fetal Rhesus D (RhD) genotype study at centers affiliated with the North American Fetal Therapy Network (NAFTNet), a nonprofit research network with expertise in the care for pregnancies at high risk of complex fetal disorders. RhD testing will be conducted at Baylor College of Medicine, Medical Genetics Laboratory using a Laboratory Developed Test (LDT) with Sequenom’s MassARRAY® system and SEQureDx™ Technology.
